Showing 1671-1680 of 3391 results for "".
New Products and Pharmacologic Developments
https://practicaldermatology.com/columns/new-products/new-products-and-pharmacologic-developments/21633/Event Marketing: Strategies to Spotlight Your Practice and Cosmetic Services
https://practicaldermatology.com/topics/practice-management/event-marketing-strategies-to-spotlight-your-practice-and-cosmetic-services/20335/The notion of hosting an event can be overwhelming, but many practices find the endeavor worthwhile. Ahead are tips for success—and a word of caution.Advanced Management Solutions for High-Grade Cutaneous Toxicities to Cancer Therapy
https://practicaldermatology.com/topics/skin-cancer-photoprotection/advanced-management-solutions-for-high-grade-cutaneous-toxicities-to-cancer-therapy/57176/The emergence of immune checkpoint inhibitors (ICIs) has fundamentally altered the prognosis for patients with advanced skin malignancies, yet the high incidence of cutaneous immune-related adverse events (irAEs) remains a significant barrier to treatment continuity. Here, we review the clinical manRecent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/20371/New in My Practice: OTC Skincare/New Products
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/new-in-my-practice-otc-skincarenew-products/23704/The Role for Rinvoq in AD Care
https://practicaldermatology.com/topics/atopic-dermatitis/the-role-for-rinvoq-in-ad-care/23663/One of the first oral JAK inhibitors approved in dermatology expands options for moderate to severe AD.Muscle Makers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/muscle-makers/23541/The newest body sculpting technologies show promise for building muscle and strength.Valeant Business Update; Melanoma Drugs Approved
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-valeant-business-update-melanoma-drugs-approved/18679/In this edition of DermWireTV from the editors of Practical Dermatology® magazine and DermWire.com, we take a look at Valeant's warning of disruption of dermatology business following its break from specialty pharmacy Philidor. Plus, an update on Melanoma Therapeutics, including approvals of ImlygicVerrucous Psoriasis
https://practicaldermatology.com/topics/psoriasis/verrucous-psoriasis/27148/Verrucous psoriasis (VP) is a rare subtype of psoriasis most commonly affecting middle-aged to older adults, with fewer than 35 reported cases within the current literature. It is characterized by symmetric wart-like, hyperkeratotic, papillomatous plaques. Treatment options are limited and variable,A First Look at Rotational Fractional Resection
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/a-first-look-at-rotational-fractional-resection/20383/A new technology offers a fresh approach to treatment of submental contouring.